2023-04-012024-03-312024-03-31falseSC307811GUIDI'S PHARMACY LTD.2024-11-0647730iso4217:GBPxbrli:pureSC3078112023-04-01SC3078112024-03-31SC3078112023-04-012024-03-31SC3078112022-04-01SC3078112023-03-31SC3078112022-04-012023-03-31SC307811bus:SmallEntities2023-04-012024-03-31SC307811bus:AuditExempt-NoAccountantsReport2023-04-012024-03-31SC307811bus:FullAccounts2023-04-012024-03-31SC307811bus:PrivateLimitedCompanyLtd2023-04-012024-03-31SC307811core:WithinOneYear2024-03-31SC307811core:AfterOneYear2024-03-31SC307811core:WithinOneYear2023-03-31SC307811core:AfterOneYear2023-03-31SC307811core:ShareCapital2024-03-31SC307811core:SharePremium2024-03-31SC307811core:RevaluationReserve2024-03-31SC307811core:OtherReservesSubtotal2024-03-31SC307811core:RetainedEarningsAccumulatedLosses2024-03-31SC307811core:ShareCapital2023-03-31SC307811core:SharePremium2023-03-31SC307811core:RevaluationReserve2023-03-31SC307811core:OtherReservesSubtotal2023-03-31SC307811core:RetainedEarningsAccumulatedLosses2023-03-31SC307811core:LandBuildings2024-03-31SC307811core:PlantMachinery2024-03-31SC307811core:Vehicles2024-03-31SC307811core:FurnitureFittings2024-03-31SC307811core:OfficeEquipment2024-03-31SC307811core:NetGoodwill2024-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2024-03-31SC307811core:ListedExchangeTraded2024-03-31SC307811core:UnlistedNon-exchangeTraded2024-03-31SC307811core:LandBuildings2023-03-31SC307811core:PlantMachinery2023-03-31SC307811core:Vehicles2023-03-31SC307811core:FurnitureFittings2023-03-31SC307811core:OfficeEquipment2023-03-31SC307811core:NetGoodwill2023-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2023-03-31SC307811core:ListedExchangeTraded2023-03-31SC307811core:UnlistedNon-exchangeTraded2023-03-31SC307811core:LandBuildings2023-04-012024-03-31SC307811core:PlantMachinery2023-04-012024-03-31SC307811core:Vehicles2023-04-012024-03-31SC307811core:FurnitureFittings2023-04-012024-03-31SC307811core:OfficeEquipment2023-04-012024-03-31SC307811core:NetGoodwill2023-04-012024-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-31SC307811core:ListedExchangeTraded2023-04-012024-03-31SC307811core:UnlistedNon-exchangeTraded2023-04-012024-03-31SC307811core:MoreThanFiveYears2023-04-012024-03-31SC307811core:Non-currentFinancialInstruments2024-03-31SC307811core:Non-currentFinancialInstruments2023-03-31SC307811dpl:CostSales2023-04-012024-03-31SC307811dpl:DistributionCosts2023-04-012024-03-31SC307811core:LandBuildings2023-04-012024-03-31SC307811core:PlantMachinery2023-04-012024-03-31SC307811core:Vehicles2023-04-012024-03-31SC307811core:FurnitureFittings2023-04-012024-03-31SC307811core:OfficeEquipment2023-04-012024-03-31SC307811dpl:AdministrativeExpenses2023-04-012024-03-31SC307811core:NetGoodwill2023-04-012024-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-31SC307811dpl:GroupUndertakings2023-04-012024-03-31SC307811dpl:ParticipatingInterests2023-04-012024-03-31SC307811dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-31SC307811core:ListedExchangeTraded2023-04-012024-03-31SC307811dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-31SC307811core:UnlistedNon-exchangeTraded2023-04-012024-03-31SC307811dpl:CostSales2022-04-012023-03-31SC307811dpl:DistributionCosts2022-04-012023-03-31SC307811core:LandBuildings2022-04-012023-03-31SC307811core:PlantMachinery2022-04-012023-03-31SC307811core:Vehicles2022-04-012023-03-31SC307811core:FurnitureFittings2022-04-012023-03-31SC307811core:OfficeEquipment2022-04-012023-03-31SC307811dpl:AdministrativeExpenses2022-04-012023-03-31SC307811core:NetGoodwill2022-04-012023-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-31SC307811dpl:GroupUndertakings2022-04-012023-03-31SC307811dpl:ParticipatingInterests2022-04-012023-03-31SC307811dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-31SC307811core:ListedExchangeTraded2022-04-012023-03-31SC307811dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-31SC307811core:UnlistedNon-exchangeTraded2022-04-012023-03-31SC307811core:NetGoodwill2024-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2024-03-31SC307811core:LandBuildings2024-03-31SC307811core:PlantMachinery2024-03-31SC307811core:Vehicles2024-03-31SC307811core:FurnitureFittings2024-03-31SC307811core:OfficeEquipment2024-03-31SC307811core:AfterOneYear2024-03-31SC307811core:WithinOneYear2024-03-31SC307811core:ListedExchangeTraded2024-03-31SC307811core:UnlistedNon-exchangeTraded2024-03-31SC307811core:ShareCapital2024-03-31SC307811core:SharePremium2024-03-31SC307811core:RevaluationReserve2024-03-31SC307811core:OtherReservesSubtotal2024-03-31SC307811core:RetainedEarningsAccumulatedLosses2024-03-31SC307811core:NetGoodwill2023-03-31SC307811core:IntangibleAssetsOtherThanGoodwill2023-03-31SC307811core:LandBuildings2023-03-31SC307811core:PlantMachinery2023-03-31SC307811core:Vehicles2023-03-31SC307811core:FurnitureFittings2023-03-31SC307811core:OfficeEquipment2023-03-31SC307811core:AfterOneYear2023-03-31SC307811core:WithinOneYear2023-03-31SC307811core:ListedExchangeTraded2023-03-31SC307811core:UnlistedNon-exchangeTraded2023-03-31SC307811core:ShareCapital2023-03-31SC307811core:SharePremium2023-03-31SC307811core:RevaluationReserve2023-03-31SC307811core:OtherReservesSubtotal2023-03-31SC307811core:RetainedEarningsAccumulatedLosses2023-03-31SC307811core:NetGoodwill2022-04-01SC307811core:IntangibleAssetsOtherThanGoodwill2022-04-01SC307811core:LandBuildings2022-04-01SC307811core:PlantMachinery2022-04-01SC307811core:Vehicles2022-04-01SC307811core:FurnitureFittings2022-04-01SC307811core:OfficeEquipment2022-04-01SC307811core:AfterOneYear2022-04-01SC307811core:WithinOneYear2022-04-01SC307811core:ListedExchangeTraded2022-04-01SC307811core:UnlistedNon-exchangeTraded2022-04-01SC307811core:ShareCapital2022-04-01SC307811core:SharePremium2022-04-01SC307811core:RevaluationReserve2022-04-01SC307811core:OtherReservesSubtotal2022-04-01SC307811core:RetainedEarningsAccumulatedLosses2022-04-01SC307811core:AfterOneYear2023-04-012024-03-31SC307811core:WithinOneYear2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:CostValuation2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-31SC307811core:Non-currentFinancialInstrumentscore:CostValuation2024-03-31SC307811core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-31SC307811core:Non-currentFinancialInstrumentscore:CostValuation2023-03-31SC307811core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-31SC307811core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-31SC307811bus:Director12023-04-012024-03-31SC307811bus:Director22023-04-012024-03-31SC307811bus:Director32023-04-012024-03-31SC307811bus:Director42023-04-012024-03-31SC307811core:FurnitureFittingsToolsEquipment2023-03-31SC307811core:FurnitureFittingsToolsEquipment2023-04-012024-03-31SC307811core:FurnitureFittingsToolsEquipment2024-03-31

GUIDI'S PHARMACY LTD.

Registered Number
SC307811
(Scotland)

Unaudited Financial Statements for the Year ended
31 March 2024

GUIDI'S PHARMACY LTD.
Company Information
for the year from 1 April 2023 to 31 March 2024

Directors

D Guidi
N Robbie
S Guidi
V Guidi

Company Secretary

V Guidi

Registered Address

139 Thurston Road
Hillington
Glasgow
G52 2AZ

Registered Number

SC307811 (Scotland)
GUIDI'S PHARMACY LTD.
Balance Sheet as at
31 March 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets4179,192194,752
179,192194,752
Current assets
Stocks567,93180,416
Debtors6243,729263,478
Cash at bank and on hand875,233793,253
1,186,8931,137,147
Creditors amounts falling due within one year7(393,840)(589,360)
Net current assets (liabilities)793,053547,787
Total assets less current liabilities972,245742,539
Provisions for liabilities8(19,414)(21,591)
Net assets952,831720,948
Capital and reserves
Called up share capital1002
Profit and loss account952,731720,946
Shareholders' funds952,831720,948
The financial statements were approved and authorised for issue by the Board of Directors on 6 November 2024, and are signed on its behalf by:
D Guidi
Director
Registered Company No. SC307811
GUIDI'S PHARMACY LTD.
Notes to the Financial Statements
for the year ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2011, has now been fully amortised.
Tangible fixed assets and depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Reducing balance (%)Straight line (years)
Fixtures and fittings25-
Vehicles25-
Office Equipment-33.33
Stocks and work in progress
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets, which include certain debtors and cash and bank balances, are initially measured at transaction price including transactions costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Basic financial liabilities, including certain creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method. Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.
2.Average number of employees

20242023
Average number of employees during the year3030
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 231,425,0001,425,000
At 31 March 241,425,0001,425,000
Amortisation and impairment
At 01 April 231,425,0001,425,000
At 31 March 241,425,0001,425,000
Net book value
At 31 March 24--
At 31 March 23--
4.Tangible fixed assets

Land & buildings

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 April 2370,0008,995249,67123,741352,407
Additions-19,050-58219,632
Disposals-(8,995)-(12,640)(21,635)
At 31 March 2470,00019,050249,67111,683350,404
Depreciation and impairment
At 01 April 23-4,146129,97623,533157,655
Charge for year-3,28327,17938630,848
On disposals-(4,651)-(12,640)(17,291)
At 31 March 24-2,778157,15511,279171,212
Net book value
At 31 March 2470,00016,27292,516404179,192
At 31 March 2370,0004,849119,695208194,752
5.Stocks

2024

2023

££
Other stocks67,93180,416
Total67,93180,416
6.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables196,038210,171
Other debtors47,69153,307
Total243,729263,478
7.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables243,204259,719
Taxation and social security98,41983,960
Other creditors50,216239,816
Accrued liabilities and deferred income2,0015,865
Total393,840589,360
8.Provisions for liabilities

2024

2023

££
Net deferred tax liability (asset)19,41421,591
Total19,41421,591
9.Controlling party
The company is controlled by the directors.